[Psychotropic drug treatment in dementia disorders].
Richartz
E
E
Universitätsklinik für Psychiatrie und Psychotherapie Tübingen, Tuebingen. elke.richartz@med.uni-tuebingen.de
Schott
K J
KJ
Wormstall
H
H
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism / Q000502:physiology; D000928:Antidepressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy* / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D018698:Glutamic Acid / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D008559:Memantine / Q000494:pharmacology / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
D000928:Antidepressive Agents; D002800:Cholinesterase Inhibitors; D011619:Psychotropic Drugs; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D008559:Memantine